Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al. New England Journal of Medicine 2021;385:503-515.
What it found
HbA1c fell by 2.01% to 2.30% with tirzepatide vs 1.86% with semaglutide, and weight loss was 1.9 to 5.5 kg greater with tirzepatide. Nausea (17-22% vs 18%), diarrhoea and vomiting were similar between drugs. Serious adverse events: 5-7% with tirzepatide vs 3% with semaglutide.
Limitations
Open-label. Semaglutide was compared at 1 mg, lower than the 2.4 mg dose used for weight management. Adults with type 2 diabetes on metformin.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.